Literature DB >> 22659496

The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway.

Wanjin Hong1, Kun-Liang Guan.   

Abstract

The Hippo signaling pathway was initially defined by genetic studies in Drosophila to regulate tissue growth and organ size [1,2]. This pathway is highly conserved in mammals and dysregulation of the Hippo pathway has been implicated in human cancer. Although the exact extracellular signal that controls the Hippo pathway is currently unknown, compelling evidence supports a critical role of the Hippo pathway in cell contact inhibition, which is a property commonly lost in cancer cells. Many molecules, such as the merlin tumor suppressor protein, have been identified as regulating the activity of the core Hippo pathway components [1,2]. Acting downstream are two key transcription co-activators, YAP and TAZ, which mediate the major gene regulation and biological functions of the Hippo pathway. This article will focus on the physiological function and molecular regulation of YAP/TAZ and its Drosophila homolog Yki.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22659496      PMCID: PMC3459069          DOI: 10.1016/j.semcdb.2012.05.004

Source DB:  PubMed          Journal:  Semin Cell Dev Biol        ISSN: 1084-9521            Impact factor:   7.727


  83 in total

1.  Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics.

Authors:  Piergiorgio Modena; Elena Lualdi; Federica Facchinetti; Joris Veltman; James F Reid; Simone Minardi; Irene Janssen; Felice Giangaspero; Marco Forni; Gaetano Finocchiaro; Lorenzo Genitori; Flavio Giordano; Riccardo Riccardi; Eric F P M Schoenmakers; Maura Massimino; Gabriella Sozzi
Journal:  J Clin Oncol       Date:  2006-11-20       Impact factor: 44.544

2.  Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma.

Authors:  Antoine M Snijders; Brian L Schmidt; Jane Fridlyand; Nusi Dekker; Daniel Pinkel; Richard C K Jordan; Donna G Albertson
Journal:  Oncogene       Date:  2005-06-16       Impact factor: 9.867

3.  TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway.

Authors:  Qun-Ying Lei; Heng Zhang; Bin Zhao; Zheng-Yu Zha; Feng Bai; Xin-Hai Pei; Shimin Zhao; Yue Xiong; Kun-Liang Guan
Journal:  Mol Cell Biol       Date:  2008-01-28       Impact factor: 4.272

4.  Multiple microalterations detected at high frequency in oral cancer.

Authors:  Corisande Baldwin; Cathie Garnis; Lewei Zhang; Miriam P Rosin; Wan L Lam
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

5.  Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65.

Authors:  Elizabeth M Morin-Kensicki; Brian N Boone; Michael Howell; Jaclyn R Stonebraker; Jeremy Teed; James G Alb; Terry R Magnuson; Wanda O'Neal; Sharon L Milgram
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

6.  Structural insights into the YAP and TEAD complex.

Authors:  Ze Li; Bin Zhao; Ping Wang; Fei Chen; Zhenghong Dong; Huirong Yang; Kun-Liang Guan; Yanhui Xu
Journal:  Genes Dev       Date:  2010-02-01       Impact factor: 11.361

7.  YAP1 increases organ size and expands undifferentiated progenitor cells.

Authors:  Fernando D Camargo; Sumita Gokhale; Jonathan B Johnnidis; Dongdong Fu; George W Bell; Rudolf Jaenisch; Thijn R Brummelkamp
Journal:  Curr Biol       Date:  2007-11-01       Impact factor: 10.834

8.  The scalloped gene encodes a novel, evolutionarily conserved transcription factor required for sensory organ differentiation in Drosophila.

Authors:  S Campbell; M Inamdar; V Rodrigues; V Raghavan; M Palazzolo; A Chovnick
Journal:  Genes Dev       Date:  1992-03       Impact factor: 11.361

9.  TAZ promotes PC2 degradation through a SCFbeta-Trcp E3 ligase complex.

Authors:  Yu Tian; Robert Kolb; Jeong-Ho Hong; John Carroll; Dawei Li; John You; Roderick Bronson; Michael B Yaffe; Jing Zhou; Thomas Benjamin
Journal:  Mol Cell Biol       Date:  2007-07-16       Impact factor: 4.272

10.  In vivo analysis of Yorkie phosphorylation sites.

Authors:  H Oh; K D Irvine
Journal:  Oncogene       Date:  2009-03-30       Impact factor: 9.867

View more
  197 in total

1.  Deacetylation of tumor-suppressor MST1 in Hippo pathway induces its degradation through HBXIP-elevated HDAC6 in promotion of breast cancer growth.

Authors:  L Li; R Fang; B Liu; H Shi; Y Wang; W Zhang; X Zhang; L Ye
Journal:  Oncogene       Date:  2015-12-14       Impact factor: 9.867

2.  The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.

Authors:  Luping Lin; Amit J Sabnis; Elton Chan; Victor Olivas; Lindsay Cade; Evangelos Pazarentzos; Saurabh Asthana; Dana Neel; Jenny Jiacheng Yan; Xinyuan Lu; Luu Pham; Mingxue M Wang; Niki Karachaliou; Maria Gonzalez Cao; Jose Luis Manzano; Jose Luis Ramirez; Jose Miguel Sanchez Torres; Fiamma Buttitta; Charles M Rudin; Eric A Collisson; Alain Algazi; Eric Robinson; Iman Osman; Eva Muñoz-Couselo; Javier Cortes; Dennie T Frederick; Zachary A Cooper; Martin McMahon; Antonio Marchetti; Rafael Rosell; Keith T Flaherty; Jennifer A Wargo; Trever G Bivona
Journal:  Nat Genet       Date:  2015-02-09       Impact factor: 38.330

3.  YAP suppresses gluconeogenic gene expression through PGC1α.

Authors:  Yue Hu; Dong-Ju Shin; Hui Pan; Zhiqiang Lin; Jonathan M Dreyfuss; Fernando D Camargo; Ji Miao; Sudha B Biddinger
Journal:  Hepatology       Date:  2017-10-30       Impact factor: 17.425

Review 4.  VGLL4 is a transcriptional cofactor acting as a novel tumor suppressor via interacting with TEADs.

Authors:  Xiaochong Deng; Lin Fang
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

5.  Immunohistochemical Profile of Tumor Suppressor Proteins RASSF1A and LATS1/2 in Relation to p73 and YAP Expression, of Human Inflammatory Bowel Disease and Normal Intestine.

Authors:  Pinelopi Nterma; Eleni Panopoulou; Eleni Papadaki-Petrou; Martha Assimakopoulou
Journal:  Pathol Oncol Res       Date:  2019-01-02       Impact factor: 3.201

6.  Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor.

Authors:  Ana Sebio; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2015-09-17       Impact factor: 12.531

7.  Crumbs promotes expanded recognition and degradation by the SCF(Slimb/β-TrCP) ubiquitin ligase.

Authors:  Paulo Ribeiro; Maxine Holder; David Frith; Ambrosius P Snijders; Nicolas Tapon
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

8.  Screening with a novel cell-based assay for TAZ activators identifies a compound that enhances myogenesis in C2C12 cells and facilitates muscle repair in a muscle injury model.

Authors:  Zeyu Yang; Kentaro Nakagawa; Aradhan Sarkar; Junichi Maruyama; Hiroaki Iwasa; Yijun Bao; Mari Ishigami-Yuasa; Shigeru Ito; Hiroyuki Kagechika; Shoji Hata; Hiroshi Nishina; Shinya Abe; Masanobu Kitagawa; Yutaka Hata
Journal:  Mol Cell Biol       Date:  2014-02-18       Impact factor: 4.272

9.  G protein-coupled receptors engage the mammalian Hippo pathway through F-actin: F-Actin, assembled in response to Galpha12/13 induced RhoA-GTP, promotes dephosphorylation and activation of the YAP oncogene.

Authors:  Laura Regué; Fan Mou; Joseph Avruch
Journal:  Bioessays       Date:  2013-03-01       Impact factor: 4.345

10.  Transformation by Polyomavirus Middle T Antigen Involves a Unique Bimodal Interaction with the Hippo Effector YAP.

Authors:  Cecile Rouleau; Arun T Pores Fernando; Justin H Hwang; Nathalie Faure; Tao Jiang; Elizabeth A White; Thomas M Roberts; Brian S Schaffhausen
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.